N-(2-methoxyethyl)-2-morpholinoethylamine | 819813-91-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: N-(2-methoxyethyl)-2-morpholinoethylamine
• 英文别名: N-(2-methoxyethyl)-2-morpholin-4-ylethanamine
• CAS: 819813-91-7
• 化学式: C₉H₂₀N₂O₂
• mdl: MFCD11153667
• 分子量: 188.27
• InChiKey: PMKBMIGIBUMLFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  33.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(2-methoxyethyl)-2-morpholinoethylamine 、 4-氟-2-硝基苯甲醛 以 二甲基亚砜 为溶剂， 反应 3.0h， 生成 4-[N-(2-methoxyethyl)-N-(2-morpholinoethyl)amino]-2-nitrobenzaldehyde
  参考文献：
  名称：

  IGF-1R INHIBITOR

  摘要：

  公开号：

  EP1847532B1

文献信息

• 2-Aryl Imidazo[1,2-a]Pyridine-3-Acetamide Derivatives, Preparation Methods and Uses Thereof
  申请人：Yang Rifang

  公开号：US20130203754A1

  公开（公告）日：2013-08-08

  Disclosed are 2-arylimidazo[1,2- a ]pyridine-3-acetamide derivatives represented by formula I, their tautomer, racemate or optical isomer, their pharmaceutically acceptable salt, or their solvates, wherein R 1 , R 2 , R 3 and R 4 are defined as in the specification. Preparation methods of said compounds and use of said compounds in treating and/or preventing central nervous system disease associated with TSPO functional disorder

  公开了由式I表示的2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物，它们的互变体、消旋体或光学异构体，它们的药学上可接受的盐，或它们的溶剂合物，其中R1、R2、R3和R4如规范中定义。所述化合物的制备方法以及所述化合物在治疗和/或预防与TSPO功能紊乱相关的中枢神经系统疾病中的用途。
• [EN] MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS, AND METHODS OF MAKING AND USING SAME<br/>[FR] INHIBITEURS DU FACTEUR INHIBITEUR DE LA MIGRATION DES MACROPHAGES, ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：UNIV YALE

  公开号：WO2022093817A1

  公开（公告）日：2022-05-05

  The present disclosure provides inhibitors of MIF tautomerase activity. In certain embodiments, the compounds inhibitors are useful in treating or preventing inflammatory and/or auto-immune diseases. In other embodiments, the compounds are useful in reversing, ameliorating, and/or preventing tumor growth. In yet other embodiments, the compounds are useful in reversing, ameliorating, and/or preventing angiogenesis.

  本公开提供了MIF异构酶活性抑制剂。在某些实施例中，这些化合物抑制剂在治疗或预防炎症和/或自身免疫性疾病方面是有用的。在其他实施例中，这些化合物在逆转、改善和/或预防肿瘤生长方面是有用的。在另一些实施例中，这些化合物在逆转、改善和/或预防血管生成方面是有用的。
• Hsp90 FAMILY PROTEIN INHIBITORS
  申请人：Nara Shinji

  公开号：US20090247522A1

  公开（公告）日：2009-10-01

  The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR 7 R 8 or the like; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R 3 and R 5 , which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R 4 and R 6 , which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

  本发明提供了Hsp90家族蛋白抑制剂，其包含作为活性成分的苯甲酰化合物，其通式表示为（I）：（其中n表示0到10的整数；R1表示取代或未取代的低烷氧基，取代或未取代的低烷氧羰基，CONR7R8或类似物；R2表示取代或未取代的芳基，取代或未取代的芳香杂环基或类似物；R3和R5，可以相同也可以不同，分别表示氢原子，取代或未取代的低烷基，取代或未取代的低烯基或类似物；R4和R6，可以相同也可以不同，分别表示氢原子，卤素，取代或未取代的低烷基，取代或未取代的芳基或类似物）或其前药，或其药学上可接受的盐。
• Hsp90 family protein inhibitors
  申请人：Nara Shinji

  公开号：US20070032532A1

  公开（公告）日：2007-02-08

  The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR 7 R 8 or the like; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R 3 and R 5 , which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R 4 and R 6 , which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

  本发明提供了Hsp90家族蛋白抑制剂，其作为活性成分包括由通式（I）表示的苯甲酰化合物： （其中，n代表0至10的整数；R1代表取代或未取代的较低烷氧基、取代或未取代的较低烷氧羰基、CONR7R8等；R2代表取代或未取代的芳基、取代或未取代的芳香族杂环基等；R3和R5，可以相同也可以不同，每个代表氢原子、取代或未取代的较低烷基、取代或未取代的较低烯基等；R4和R6，可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基、取代或未取代的芳基等）或其前药，或所述苯甲酰化合物或其前药的药学上可接受的盐。
• IGF-1R inhibitor
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US07605272B2

  公开（公告）日：2009-10-20

  The present invention provides a type I insulin-like growth factor receptor (IGF-1R) inhibitor comprising, as an active ingredient, an indazole derivative represented by Formula (I): wherein R1 represents —NR4R5 [wherein R4 represents a hydrogen atom or the like, R5 represents substituted or unsubstituted lower alkyl, —C(═O)R6 (wherein R6 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like), or the like], or the like, and R2 and R3 may be the same or different and each represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkoxy, or the like} or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种I型胰岛素样生长因子受体（IGF-1R）抑制剂，其包括以式（I）表示的吲唑衍生物作为活性成分：其中R1表示—NR4R5 [其中R4表示氢原子或类似物，R5表示取代或未取代的低碳基，—C（═O）R6（其中R6表示取代或未取代的低碳基，取代或未取代的芳基或类似物）或类似物]或类似物，R2和R3可以相同也可以不同，每个表示氢原子，羟基，取代或未取代的低烷氧基或类似物，或类似物。还包括其药学上可接受的盐等。